The combination of theasinensin A and nimotuzumab has a remarkable inhibitory effect on NSCLC tumor growth by means of inhibiting the EGFR signaling pathways and the tumor microenvironment. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.